

## **A novel prediction model for immunotherapy induced pneumonitis prediction based on Chest CT and electronic health record**

Qing Lyu<sup>1,2</sup>, Hongyu Yuan<sup>1</sup>, Zhen Lin<sup>2</sup>, Janardhana Ponnatapura<sup>1\*</sup>, Christopher T Whitlow<sup>1,2\*</sup>

Department of Radiology, Wake Forest University School of Medicine, Winston-Salem, NC, 27103, USA

Department of Biomedical Engineering, Wake Forest University School of Medicine, Winston-Salem, NC, 27103, USA

### **Abstract**

Immune checkpoint inhibitors (ICIs) have been extensively used for the treatment of non-small cell lung cancer patients in recent years, providing a significant survival benefit. However, a major drawback of ICIs-related immunotherapy is the risk of developing post-surgical pneumonitis. In this study, we propose a deep learning-embedded, multi-modality prediction approach to assess whether patients will develop ICI-pneumonitis after receiving ICIs-based immunotherapy. This approach utilizes multi-modal data, including clinical data and pre-treatment lung screening computed tomography (CT) images. We extracted three types of features: 1) deep learning features from CT scans using a pretrained vision transformer, 2) radiomic features from CT scans using predefined radiomic algorithms, and 3) clinical features from patients' clinical records. We then compared multiple machine learning algorithms for prediction based on these extracted features. Our results demonstrated a prediction accuracy of 0.823 and an area under the receiver operating characteristic curve of 0.895.

**Keywords:** Immunotherapy induced pneumonitis, immune checkpoint inhibitor, lung cancer, machine learning, deep learning, radiomics, computed tomography

### **Introduction**

Lung cancer is the most frequently diagnosed cancer and the leading cause of cancer death worldwide<sup>1</sup>. Non-small cell lung cancer (NSCLC) is the most common subtype, accounting for approximately 85% of all lung cancer cases<sup>2</sup>. Recently, immunotherapy, particularly immune checkpoint inhibitors (ICIs), has demonstrated superior outcomes in the treatment of NSCLC, significantly improving overall survival compared to chemotherapy<sup>3,4</sup>. ICIs provoke immune reactions against cancer cells by blocking inhibitory receptors such as programmed cell death protein-1 (PD-1), programmed death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte antigen 4 (CTLA-4)<sup>5-7</sup>. However, ICIs can also induce autoimmune reactions that are harmful to healthy tissues by disrupting normal immune system homeostasis, resulting in immune-related adverse events (irAEs)<sup>8</sup>. ICI-related pneumonitis (ICI-P) is a rare but life threatening irAE, with an overall incidence rate of 3-6% and a mortality rate of 22-33% for severe cases (grade 3-4)<sup>9-11</sup>. ICI-P can potentially cause significant morbidity, leading to the discontinuation of therapy and even mortality<sup>8</sup>. Clinical diagnosis of ICI-P is challenging due to its nonspecific symptoms and similarities to other pulmonary conditions<sup>12</sup>. There is no gold standard for clinical diagnosis, making it necessary to develop pretreatment ICI-P prediction methods.

Multiple studies have investigated the feasibility of predicting ICI-P before NSCLC patients receive immunotherapy. Risk factors such as tumor histologic type, ICIs selection, combination therapy, preexisting diseases (e.g. interstitial lung disease and extrathoracic metastasis), smoking history, and radiotherapy history are believed to influence the incidence rate of ICI-P<sup>10,13-19</sup>. Based on these findings, several prediction models have been developed. Jia *et al.* proposed a dynamic online hypertension nomogram to predict ICI-P for NSCLC patients<sup>20</sup>. Gong *et al.* developed a machine learning algorithm to identify and predict ICI-P based on eleven predictors<sup>21</sup>. Li and Xu both built risk assessment nomograms for ICI-P prediction<sup>22,23</sup>. In addition to using risk factors, researchers hypothesize that chest CT images contain discriminative information for ICI-P prediction. To validate this hypothesis, Colen *et al.* proposed a radiomics-based ICI-P prediction method, in extracting 1860 radiomic features from chest computed tomography (CT) images<sup>24</sup>. Mu *et al.* developed a radiomics nomogram to predict severe irAEs using fluorine-18 fluorodeoxyglucose positron emission tomography (PET) and CT images<sup>25</sup>. Cheng *et al.* created a deep learning embedded nomogram approach for ICI-P prediction, where a CT score, calculated from five radiology features extracted by a neural network, was input into a nomogram among with three other features for the final prediction<sup>26</sup>. Tan *et al.* constructed a multimodal deep learning model based on 3D CT images and clinical data, achieving an overall accuracy of 0.92 for ICI-P prediction through five-fold cross-validation<sup>27</sup>. Additionally, chest CT images can help discriminate different types of pneumonitis. Tohidinezhad *et al.* explored the feasibility of establishing a prediction model to differentiate ICI-P from other types of pneumonitis in NSCLC patients undergoing immunotherapy<sup>28</sup>. Mallio *et al.* utilized a deep learning algorithm based on chest CT images to distinguish coronavirus disease 2019 (COVID-19) pneumonia from ICI-P<sup>29</sup>.

Differing from existing studies, we propose a multimodal ICI-P prediction model utilizing three types of features: deep learning features, radiomic features, and clinical features. Deep learning features are extracted from a pretrained vision transformer (ViT), radiomic features are derived from predefined radiomic algorithms, and clinical features are obtained from patients' clinical database. After feature selection, the selected features are input into the proposed ICI-P prediction model to predict the likelihood of ICI-P development following immunotherapy.

## Methodology

### Dataset

We collected data from 1,254 NSCLC patients who received immunotherapy between 2005 and 2021 at Wake Forest Baptist Medical Center. Among these, 51 patients developed ICI-P and were included in the experimental group for this study. Conversely, we randomly selected 41 patients who didn't have ICI-P after immunotherapy to serve as the control group. Table 1 presents the demographic information of the patients. For each patient, we collected both the most recent chest CT scan taken before the first immunotherapy session and the corresponding clinical data.

Table 1. Patient demographic information

	ICI-P	Control
Amount	51	41
Gender	F: 21, M: 30	F: 26, M: 15
Age	62.3±10.9	68.7±11.4
BMI	28.4±7.0	23.9±5.3

### Image processing

We first preprocessed the CT images to unify voxel resolution to 1x1x1 mm using nearest interpolation and cropped each image to a size of 512x512. At the same time, the pixel intensity was truncated to a range between -2100 and 100 Hounsfield units (HU). Lung segmentation was then implemented using three different networks: Lungmask<sup>30</sup>, nnUNet<sup>31</sup>, and Covid-19 MIScnn<sup>32</sup>. To achieve accurate lung segmentation, we developed a strategy that combines the results from these three networks. First, we created a union of the results from Lungmask, nnUNet, and Covid-19 MIScnn. Then, we manually checked each result from the previous step and corrected misclassified regions.




Figure 1. Lung segmentation results. From left to right: CT images, Lungmask segmentation, Covid-19 MIScnn, nnUNet, union results, and final results after manual correction. Blue arrows show false positive regions and yellow arrows demonstrate false negative regions.

### *Vision transformer*

Given the huge success of transformers in natural language processing, ViT have recently been proposed as a competitive alternative to convolutional neural networks for various computer vision task, such as image classification, object detection, and semantic image segmentation<sup>33</sup>. In this study, we pretrained a ViT model to extract deep learning features from 3D CT images. A ViT-base model was pretrained with a hidden size of 768, 12 heads, and a depth of 12, following the strategy outlined by Niu *et al.*<sup>34</sup>.

During deep learning feature extraction, the CT images were divided into multiple 4x16x16 patches and fed into the pretrained ViT model. Each input patch produced a vector with a dimension of 768, and the summation of all vectors was used as the final set of deep learning features. For each patient, there were 768 deep learning features extracted.

### *Radiomics*

We utilized the Python Pyradiomics library for radiomic feature extraction<sup>35</sup>. To enhance the utilization of information within CT images, wavelet transform was applied before the feature extraction process. For each patient, there were 863 radiomic features extracted, categorized into 8 major categories: first order statistics, shape-based (2D), shape-based (3D), gray level co-occurrence matrix, gray level run length

matrix, gray level size zone matrix, neighboring gray tone difference matrix, and gray level dependence matrix.

### *Clinical data*

Ten clinical features were extracted from patients' electronic health record: 1) pack years, 2) age, 3) body mass index (BMI), 4) baseline oxygen dependence, 5) whether received surgery prior to immunotherapy, 6) whether received radiation prior to immunotherapy, 7) eastern cooperative oncology group performance status (ECOG PS) at the time of immunotherapy, 8) choice of immunotherapy, 9) whether immuno-oncology (IO) given concurrently with chemotherapy, and 10) total cycles of IO given. Since some clinical features are categorical and not represented numerically, we converted these features to one-hot encoding for prediction.

### *Feature selection*

After feature extraction, we obtained a total of 768 deep learning features, 863 radiomic features, and 10 clinical features. To remove redundant and non-relevant features, we performed feature selection using the Chi-square test and Student's t-test. For deep learning and radiomic features, we retained only the 25 most significant features of each type. All 10 clinical features were kept. As a result, a total of 60 features were utilized for prediction after feature selection.

### *Prediction model*

We utilized the Python PyCaret library to establish ICI-P models. Ten different prediction models were compared, including logistic regression, K neighbors classifier, support vector machine, gradient boosting classifier, ada boost classifier, decision tree classifier, light gradient boosting machine, extra trees classifier, naïve bayes, and random forest classifier.

### *Experimental details*

We pretrained the ViT model on 2,000 chest CT scans collected by Wake Forest Baptist Medical Center between 2015 and 2021. The pretraining process was carried out for 100 epochs on an Nvidia A100 GPU. During pretraining, the original CT images were divided into multiple smaller patches of size 64 by 64 by 64. When combining features extracted from different approaches, we first normalized each feature to standardize feature values, mitigating potential issues caused by mismatched feature value magnitudes. Clinical features were processed through either one-hot encoding or manual labeling to convert discrete features into a continuous domain. When using PyCaret for ICI-P prediction, three-fold cross validation was employed.

## **Results**

### *Patient characteristics*

A total of 92 NLCSC patients who received at least one cycle of immunotherapy at Wake Forest Baptist Medical Center were enrolled in this study. Among these patients, 51 developed ICI-P, with a median time

of 149 days between the initial immunotherapy date and ICI-P diagnosis date. Of the patients who developed ICI-P, 45% received Pembrolizumab, 31% received Nivolumab, 14% received Durvalumab, 4% received Atezolizumab, and the remaining received a combination of immune checkpoint inhibitors. All ICI-P patients were diagnosed with pneumonitis of Grade 2 or higher: 44% had Grade 2, 44% had Grade 3, 7% had Grade 4, and 9% had Grand 5 pneumonitis. The 41 patients who didn't develop ICI-P were used as the control group. Among them, 62% received Pembrolizumab, 17% received Nivolumab, 5% received Durvalumab, 14% received Atezolizumab, and 2% received Lenvatinib.

When conducting Chi-square test and Student's t-test for clinical feature selection, we identified four features, including total cycles of IO given, pack years, BMI at diagnosis, and age, that showed significantly differences between ICI-P and control groups, as shown in Table 2. A nomogram was constructed as a quantitative method to predict the risk of ICI-P in NSCLC patients, as show in Figure 2.

Table 2. Identifying significant clinical features based on Chi-square test and Student's t-test.

Clinical features		p-value
Total cycles of IO given		<0.001
Pack years		<0.001
BMI at diagnosis		<0.001
Age		<0.001
Received radiation prior to immunotherapy	Yes	0.035
	No	0.072
ECOG PS at the time of immunotherapy		0.054
Choice of immunotherapy	Pembrolizumab	0.178
	Nivolumab	0.353
	Durvalumab	0.078
	Atezolizumab	0.453
	Other	0.381
Received surgery prior to immunotherapy	Yes	0.099
	No	0.402
Baseline oxygen dependence	Yes	0.130
	No	0.769
IO given concurrently with chemotherapy	Yes	0.141
	No	0.220




Figure 2. Nomogram of the ICI-P prediction model based on selected clinical features.

#### *ICI-pneumonitis prediction result based on all types of features*

Metrics such as accuracy, area under the receiver operating characteristic curve (AUC), recall, precision, and F1 score were utilized to evaluate the performance of the ICI-P prediction models. Table 3 presents a comparison of different prediction models generated using PyCaret based on all selected multi-modal features. It can be found that logistic regression achieved the best performance in terms of accuracy, AUC, recall, and F1 score. Meanwhile, support vector machines achieved the highest precision.

Table 3. Comparison of different ICI-pneumonitis prediction models.

Model	Accuracy	AUC	Recall	Precision	F1
Logistic regression	<b>0.823</b>	<b>0.895</b>	<b>0.853</b>	0.853	<b>0.852</b>
K neighbor classifier	0.809	0.892	0.787	0.882	0.830
Support vector machines	0.783	0.824	0.664	<b>0.975</b>	0.775
Gradient boosting classifier	0.746	0.818	0.789	0.791	0.788
Ada boost classifier	0.744	0.845	0.764	0.816	0.783
Decision tree classifier	0.709	0.722	0.662	0.811	0.725
Light gradient boosting machine	0.683	0.779	0.769	0.716	0.732
Extra tree classifier	0.683	0.711	0.811	0.714	0.757
Naïve Bayes	0.658	0.618	0.791	0.700	0.736
Random forest	0.631	0.726	0.767	0.672	0.714

#### *Ablation study*

We conducted an ablation study to assess the contribution of each modality of features to the final prediction results and to demonstrate the effectiveness of the proposed method. A series of experiments were performed, building prediction models under four situations: using clinical features alone, deep learning features alone, radiomic features alone, and a combination of all features. As show in Table 4. The results indicate that using all three kinds of features together leads to higher accuracy and AUC scores compared to using each type of features individually. The only exception was the random forest model, which performed better when the prediction was based solely on clinical features.

Table 4. Comparison of multiple prediction models on different types of features.

Model	accuracy				AUC			
	Clinical	Radiomic	Deep	All	Clinical	Radiomic	Deep	All
LR	0.802	0.721	0.711	<b>0.823</b>	0.835	0.723	0.757	<b>0.895</b>
KNN	0.790	0.691	0.655	<b>0.809</b>	0.826	0.712	0.671	<b>0.892</b>
SVM	0.723	0.677	0.688	<b>0.783</b>	0.794	0.692	0.692	<b>0.824</b>
GBC	0.727	0.661	0.644	<b>0.746</b>	0.792	0.712	0.677	<b>0.818</b>
RF	<b>0.713</b>	0.555	0.577	0.631	<b>0.760</b>	0.679	0.685	0.726

LR: linear regression, KNN: k neighbors classifier, SVM: support vector machines, GBC: gradient boosting classifier, RF: random forest.

## Discussion

Immune checkpoint inhibitor immunotherapy is a revolutionary treatment for NSCLC that leverages the body's immune system to target and destroy cancer cells. ICIs significantly improve outcomes for NSCLC patients, leading to longer overall survival and durable responses for some patients compared to traditional chemotherapy<sup>3,4</sup>. However, a major side effect of ICI-related immunotherapy is the potential development of irAEs, particularly ICI-P, which, although rare, can be life-threatening. In this paper, we propose a multi-modal approach to predict the occurrence of ICI-P in patients undergoing ICI immunotherapy. The approach incorporates three types of features: clinical features from patients' electronic health records and radiomic and deep learning features extracted from CT scans. Our study demonstrates that using all three types of features together yields the best predictive performance.

In our ablation study, we found that clinical features contributed more to the final prediction results compared to radiomic and deep learning features. This is expected, as clinical features are directly related to the patients' health conditions and their treatment processes. In contrast, radiomic and deep learning features, extracted from CT scans, provide only implicit information about patients' health status. Our experiments showed that the best prediction results were achieved when all three types of features were combined. This suggests that CT scans provide additional valuable information beyond what is available in the patients' electronic health records, and this information can be effectively extracted using radiomic and deep learning algorithms.

Developing methods to predict ICI-P can lead to improved treatment outcomes. Accurate prediction of ICI-P allows for the early identification of patients who are at a higher risk of developing pneumonitis. This enables proactive monitoring, early intervention, and potentially modifying or discontinuing treatment to prevent severe outcomes. Predicting ICI-P risk can also help oncologists personalize treatment regimens. For patients at high risk, alternative therapies, dose adjustments, or combination strategies that lower the risk may be considered. In addition, predicting and managing ICI-P early can help prevent unplanned treatment interruptions, ensuring patients can continue their cancer therapy as planned and potentially improve overall outcomes.

## Reference

1. Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin*. May-Jun 2024;74(3):229-263. doi:10.3322/caac.21834
2. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. *Mayo Clin Proc*. May 2008;83(5):584-94. doi:10.4065/83.5.584
3. Doroshov DB, Sanmamed MF, Hastings K, et al. Immunotherapy in Non-Small Cell Lung Cancer: Facts and Hopes. *Clin Cancer Res*. Aug 1 2019;25(15):4592-4602. doi:10.1158/1078-0432.CCR-18-1538

4. Malhotra J, Jabbour SK, Aisner J. Current state of immunotherapy for non-small cell lung cancer. *Transl Lung Cancer Res*. Apr 2017;6(2):196-211. doi:10.21037/tlcr.2017.03.01
5. Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. *Nature*. Jan 24 2018;553(7689):446-454. doi:10.1038/nature25183
6. D'Incecco A, Andreozzi M, Ludovini V, et al. PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients. *Br J Cancer*. Jan 6 2015;112(1):95-102. doi:10.1038/bjc.2014.555
7. Reck M, Rodriguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. *N Engl J Med*. Nov 10 2016;375(19):1823-1833. doi:10.1056/NEJMoa1606774
8. Kalisz KR, Ramaiya NH, Laukamp KR, Gupta A. Immune Checkpoint Inhibitor Therapy-related Pneumonitis: Patterns and Management. *Radiographics*. Nov-Dec 2019;39(7):1923-1937. doi:10.1148/rg.2019190036
9. Naidoo J, Wang X, Woo KM, et al. Pneumonitis in Patients Treated With Anti-Programmed Death-1/Programmed Death Ligand 1 Therapy. *J Clin Oncol*. Mar 2017;35(7):709-717. doi:10.1200/JCO.2016.68.2005
10. Wang DY, Salem JE, Cohen JV, et al. Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. *JAMA Oncol*. Dec 1 2018;4(12):1721-1728. doi:10.1001/jamaoncol.2018.3923
11. Tone M, Izumo T, Awano N, et al. High mortality and poor treatment efficacy of immune checkpoint inhibitors in patients with severe grade checkpoint inhibitor pneumonitis in non-small cell lung cancer. *Thorac Cancer*. Oct 2019;10(10):2006-2012. doi:10.1111/1759-7714.13187
12. Gomatou G, Tzilas V, Kotteas E, Syrigos K, Bouros D. Immune Checkpoint Inhibitor-Related Pneumonitis. *Respiration*. 2020;99(11):932-942. doi:10.1159/000509941
13. Suresh K, Voong KR, Shankar B, et al. Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors. *J Thorac Oncol*. Dec 2018;13(12):1930-1939. doi:10.1016/j.jtho.2018.08.2035
14. Lisberg A, Cummings A, Goldman JW, et al. A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naive Patients With Advanced NSCLC. *J Thorac Oncol*. Aug 2018;13(8):1138-1145. doi:10.1016/j.jtho.2018.03.035
15. Shibaki R, Murakami S, Matsumoto Y, et al. Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody. *Cancer Immunol Immunother*. Jan 2020;69(1):15-22. doi:10.1007/s00262-019-02431-8
16. Su Q, Zhu EC, Wu JB, et al. Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis. *Front Immunol*. 2019;10:108. doi:10.3389/fimmu.2019.00108
17. Cho JY, Kim J, Lee JS, et al. Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer. *Lung Cancer*. Nov 2018;125:150-156. doi:10.1016/j.lungcan.2018.09.015
18. Zhai X, Zhang J, Tian Y, et al. The mechanism and risk factors for immune checkpoint inhibitor pneumonitis in non-small cell lung cancer patients. *Cancer Biol Med*. Aug 15 2020;17(3):599-611. doi:10.20892/j.issn.2095-3941.2020.0102
19. Lin MX, Zang D, Liu CG, Han X, Chen J. Immune checkpoint inhibitor-related pneumonitis: research advances in prediction and management. *Front Immunol*. 2024;15:1266850. doi:10.3389/fimmu.2024.1266850
20. Jia XH, Chu XL, Jiang LL, et al. Predicting checkpoint inhibitors pneumonitis in non-small cell lung cancer using a dynamic online hypertension nomogram (vol 170, pg 74, 2022). *Lung Cancer*. Sep 2022;171:121-125. doi:10.1016/j.lungcan.2022.06.015
21. Gong L, Gong J, Sun X, et al. Identification and prediction of immune checkpoint inhibitors-related pneumonitis by machine learning. *Front Immunol*. 2023;14:1138489. doi:10.3389/fimmu.2023.1138489
22. Li X, Lv F, Wang Y, Du Z. Establishment and validation of nomogram for predicting immuno checkpoint inhibitor related pneumonia. *BMC Pulm Med*. Sep 1 2022;22(1):331. doi:10.1186/s12890-022-02127-3
23. Xu H, Feng H, Zhang W, et al. Prediction of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint inhibitors based on clinical and hematological markers: Real-world evidence. *Exp Cell Res*. Jul 1 2022;416(1):113157. doi:10.1016/j.yexcr.2022.113157



24. Colen RR, Fujii T, Bilan MA, et al. Radiomics to predict immunotherapy-induced pneumonitis: proof of concept. *Invest New Drugs*. Aug 2018;36(4):601-607. doi:10.1007/s10637-017-0524-2
25. Mu W, Tunali I, Qi J, Schabath MB, Gillies RJ. Radiomics of (18)F Fluorodeoxyglucose PET/CT Images Predicts Severe Immune-related Adverse Events in Patients with NSCLC. *Radiol Artif Intell*. Jan 2020;2(1):e190063. doi:10.1148/ryai.2019190063
26. Cheng M, Lin R, Bai N, et al. Deep learning for predicting the risk of immune checkpoint inhibitor-related pneumonitis in lung cancer. *Clin Radiol*. May 2023;78(5):e377-e385. doi:10.1016/j.crad.2022.12.013
27. Tan P, Huang W, Wang L, et al. Deep learning predicts immune checkpoint inhibitor-related pneumonitis from pretreatment computed tomography images. *Front Physiol*. 2022;13:978222. doi:10.3389/fphys.2022.978222
28. Tohidinezhad F, Bontempi D, Zhang Z, et al. Computed tomography-based radiomics for the differential diagnosis of pneumonitis in stage IV non-small cell lung cancer patients treated with immune checkpoint inhibitors. *Eur J Cancer*. Apr 2023;183:142-151. doi:10.1016/j.ejca.2023.01.027
29. Mallio CA, Napolitano A, Castiello G, et al. Deep Learning Algorithm Trained with COVID-19 Pneumonia Also Identifies Immune Checkpoint Inhibitor Therapy-Related Pneumonitis. *Cancers (Basel)*. Feb 6 2021;13(4)doi:10.3390/cancers13040652
30. Hofmanninger J, Prayer F, Pan J, Röhrich S, Prosch H, Langs G. Automatic lung segmentation in routine imaging is primarily a data diversity problem, not a methodology problem. *Eur Radiol Exp*. 2020;4:1-13. doi:10.1186/s41747-020-00173-2
31. Isensee F, Jaeger PF, Kohl SAA, Petersen J, Maier-Hein KH. nnU-Net: a self-configuring method for deep learning-based biomedical image segmentation. *Nat Methods*. Feb 2021;18(2):203-211. doi:10.1038/s41592-020-01008-z
32. Muller D, Soto-Rey I, Kramer F. Robust chest CT image segmentation of COVID-19 lung infection based on limited data. *Inform Med Unlocked*. 2021;25:100681. doi:10.1016/j.imu.2021.100681
33. Han K, Wang Y, Chen H, et al. A Survey on Vision Transformer. *IEEE Trans Pattern Anal Mach Intell*. Jan 2023;45(1):87-110. doi:10.1109/TPAMI.2022.3152247
34. Niu C, Lyu Q, Carothers CD, et al. Specialty-Oriented Generalist Medical AI for Chest CT Screening. *arXiv e-prints*. 2023;doi:10.48550/arXiv.2304.02649
35. van Griethuysen JJM, Fedorov A, Parmar C, et al. Computational Radiomics System to Decode the Radiographic Phenotype. *Cancer Res*. Nov 1 2017;77(21):e104-e107. doi:10.1158/0008-5472.CAN-17-0339